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Background: The Arthroplasty Pain Experience (APEX) studies are two randomised controlled trials in primary total
hip (THR) and total knee replacement (TKR) at a large UK orthopaedics centre. APEX investigated the effect of local
anaesthetic wound infiltration (LAI), administered before wound closure, in addition to standard analgesia, on pain
severity at 12 months. This article reports results of the within-trial economic evaluations.
Methods: Cost-effectiveness was assessed from the health and social care payer perspective in relation to quality
adjusted life years (QALYs) and the primary clinical outcome, the WOMAC Pain score at 12-months follow-up. Resource
use was collected from hospital records and patient-completed postal questionnaires, and valued using unit cost
estimates from local NHS Trust finance department and national tariffs. Missing data were addressed using multiple
imputation chained equations. Costs and outcomes were compared per trial arm and plotted in cost-effectiveness
planes. If no arm was dominant (i.e., more effective and less expensive than the other), incremental cost-effectiveness
ratios were estimated. The economic results were bootstrapped incremental net monetary benefit statistics (INMB)
and cost-effectiveness acceptability curves. One-way deterministic sensitivity analyses explored any methodological
uncertainty.
Results: In both the THR and TKR trials, LAI was the dominant treatment: cost-saving and more effective than standard
care, in relation to QALYs and WOMAC Pain. Using the £20,000 per QALY threshold, in THR, the INMB was £1,125
(95 % BCI, £183 to £2,067) and the probability of being cost-effective was over 98 %. In TKR, the INMB was £264
(95 % BCI, −£710 to £1,238), but there was only 62 % probability of being cost-effective. When considering an NHS
perspective only, LAI was no longer dominant in THR, but still highly cost-effective, with an INMB of £961 (95 %
BCI, £50 to £1,873).
Conclusions: Administering LAI is a cost-effective treatment option in THR and TKR surgeries. The evidence, because
of larger QALY gain, is stronger for THR. In TKR, there is more uncertainty around the economic result, and smaller QALY
gains. Results, however, point to LAI being cheaper than standard analgesia, which includes a femoral nerve block.
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Total hip (THR) and knee replacements (TKR) are com-
mon elective procedures with over 150,000 performed
annually in the UK NHS [1]. In the USA in 2010, the es-
timated numbers of hospital discharges after THR and
TKR procedures were 332,000 and 719,000, respectively
[2]. For most patients with advanced osteoarthritis, THR
and TKR are effective in treating pain and restoring
physical function. However, some patients report chronic
joint pain after surgery. Evidence suggests that around
20 % of patients with TKR and 10 % of patients with THR
report an unfavourable pain outcome at between 3
months and 5 years post-operative [3].
Local anaesthetic wound infiltration (LAI), adminis-
tered intra-operatively before wound closure, can pro-
vide better short-term pain relief and decrease hospital
length of stay, but long term effectiveness and cost-
effectiveness evidence is lacking [4]. In a recent system-
atic review of LAI, most studies reported outcomes up
to 3 months post-surgery, and none of the studies in-
cluded an economic evaluation of the intervention [4].
The Arthroplasty Pain Experience (APEX) studies are
two randomised controlled trials, conducted at a large
UK orthopaedic centre, which investigated the effect of
intra-operative LAI, in addition to the standard anal-
gesia, on pain severity at 12 months following primary
THR and TKR for osteoarthritis [5].
The aim of this article is to report the results of the
two within-trial economic evaluations. We assess the
cost-effectiveness of LAI, in addition to the usual anal-
gesia regimen, over the 12 months following surgery,
from a health and social care payer perspective. In sec-
ondary analyses, we explore the economic results using
only a health care payer perspective. In sensitivity ana-
lyses, we explore uncertainty around costing assumptions.
This article follows the CHEERS reporting guidelines
(Additional file 1: Appendix 1) [6].
Methods
The APEX trials were approved by Southampton and
South West Hampshire Research Ethics Committee (09/
H0504/94) and all participants provided written in-
formed consent. The trials were registered as an Inter-
national Standardised Randomized Controlled Trial
(96095682) and as a Clinical Trial of an Investigational
Medicinal Product with the Medicine Healthcare and
Regulatory Authority (18524/0215/001-0001) and EudraCT
(2009– 013817–93).
The economic evaluations took a health and social
care payer perspective: the NHS and Personal Social
Services (PSS), in line with the National Institute for
Health and Care Excellence (NICE) recommendations
[7]. The APEX trials were two double-blinded single-
centre trials in patients undergoing primary THR orTKR for osteoarthritis [8]. Patients were randomised to
receive intra-operative LAI, administered before wound
closure, in addition to the standard anaesthetic regimen,
or standard anaesthesia alone. Standard anaesthetic care
consisted of a spinal anaesthetic alone or in combination
with sedation/light general anaesthetic for patients
undergoing THR surgery. In TKR, standard care also in-
cluded administering a femoral nerve block in addition
to spinal or general anaesthesia. The primary clinical
outcome was the Western Ontario and McMaster Uni-
versities Osteoarthritis Index (WOMAC) Pain Scale at
12 months post-operative [9].
The primary economic analyses alongside the APEX
trials were cost-utility analyses, whereby incremental
costs were compared with incremental quality adjusted
life years (QALYs) gained, at 12 months after surgery.
The secondary economic analyses compared the incre-
mental costs with increment health benefits measured
by the WOMAC Pain score at 12 months follow-up. In
addition, we presented results in relation to both health
outcomes from an NHS perspective only.
Health outcomes
The primary health outcome for the APEX trials eco-
nomic evaluation was the QALY. A QALY is a measure
of disease burden that weights survival by quality of life.
This generic measure allows for direct effectiveness and
cost-effectiveness comparisons between interventions
across all patient groups and health conditions. NICE
guidelines provide recommendations for UK’s societal
willingness to pay for one QALY gained [10], which al-
lows for inferences about cost-effectiveness of interven-
tions to be made. QALYs for the APEX trials were
derived using the EuroQoL questionnaire (EQ-5D-3L)
[11] completed by patients at baseline, and at 3, 6, and
12 months follow-up. The EQ-5D-3L questionnaire
comprises five dimensions: mobility, self-care, usual ac-
tivities, pain/discomfort, and anxiety/depression. Each
dimension has three levels: no problems, some prob-
lems, or severe problems.
The primary clinical outcome was the WOMAC Pain
score, completed by patients at 12 months after surgery.
WOMAC Pain scores ranged from 0–100, with lower
scores indicating more severe pain.
Resource use identification and collection
Collection of resource use data was identical for both
the THR and TKR trials and related to services used for
reasons related to the patients’ joint replacement. Re-
sources used at the treating hospital were extracted from
medical records onto study-specific proformas. These in-
cluded the initial inpatient stay for joint replacement,
and subsequent inpatient stays and outpatient visits dur-
ing the 12 months of follow-up. Initial inpatient resource
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injection in the intervention group, time spent in recov-
ery, and number of days admitted to a ward after sur-
gery. After initial hospital discharge, inpatient and
outpatient resource use data collected included the
duration, reason for visit and ward details of inpatient,
day-case admissions, accident and emergency visits, and
outpatient visits at clinics.
All other resource use was collected using patient-
completed questionnaires, administered by post at 3, 6,
and 12 months follow-up. This included secondary care
at other hospitals, community-based health care visits,
medications use, and use of social services. Community
health care included contacts with a doctor, practice
nurse, district nurse, community physiotherapist, and
occupational therapist contacts. Social services included
food at home and home care worker services, contacts
with social workers, equipment provided to patients, and
changes made to patients’ homes during the follow-up
period. We excluded services, equipment, and home
changes paid for privately by patients.
Patients were provided with resource use logs at hos-
pital discharge, and at 3 and 6 months to facilitate their
completion of these questionnaires [12]. Both the logs
and the questionnaires were tailored to the type of joint
replacement (THR or TKR). Examples of the 3-months
resource use questionnaire and log are available online
on the DIRUM (Data Instruments for Resource Use
Measurement) database [13, 14].
Valuation of resource use
Resources used during the initial hospital stay were val-
ued using unit costs obtained from the North Bristol
Trust finance department. Cost estimates for time spent
in theatre, recovery, and admissions to hospital wards
included staff time, overheads, consumables, and medi-
cations. Unit costs for the LAI injection were provided
by the Management and Procurement Department at
North Bristol NHS Trust.
For secondary care visits in the 12 months follow-up
period, we used information on the reason for inpatient
admissions, duration of episode and clinical expert ad-
vice to derive healthcare resource group codes. Health-
care resource groups and outpatient appointments by
clinical specialty, were valued using Department of
Health Reference costs [15].
Community-based resources and personal social ser-
vices were valued using Curtis’ unit costs for health and
social care [16]. Equipment and changes to patients’
homes, such as dressing aids, furniture raisers, walking
aids, and chair lifts, were financed by social services, but
provided to patients, on loan, through occupational ther-
apists and physiotherapists at North Bristol Trust. We
assumed the useful life of the equipment to be 2 yearsand valued it as the fraction of equipment cost propor-
tional to the duration of patient use. Unit costs were ob-
tained from equipment suppliers to North Bristol Trust
or online sources from other suppliers when procure-
ment costs were not available. Prescribed medications
were valued using the British National Formulary 68
[17]. Table 1 describes sources of unit cost estimates.
Data analysis
The two separate economic evaluations, for THR and
TKR, were intention-to-treat analyses and used the same
methodology. QALYs were derived for each treatment
group, attributing the quality weights from a sample of
the UK population to the patients answers to the EQ-
5D-3L questionnaire [18], at baseline (pre-operative),
and at 3, 6, and 12 months follow-up. QALYs were then
estimated using the “area under the curve approach”,
which assumes a linear change between time points [19].
Mean and standard deviations for QALYs were calcu-
lated for each group.
Costs were estimated by multiplying units of resource
use by their unit cost, reported in 2012–2013 prices
(Table 1). Resources were categorised into 17 categories.
The total cost for each patient for each of these categor-
ies was calculated as the sum of the cost of the resource
use items. For each category using all available data, we
calculated means and standard deviations for resource
use and costs by treatment group. The cost categories
were then grouped into initial inpatient stay costs,
secondary care costs during the follow-up period,
community-based health care costs including medica-
tion, and personal social service (PSS) costs. The total
individual patient cost for these four groups, as well as
total NHS costs and total NHS and PSS costs, were cal-
culated as above. Costs and outcomes were not dis-
counted because of the 1 year duration of follow-up.
Incremental costs for the four main cost groupings, and
QALY and WOMAC differences between groups, were
then estimated using ordinary least squares regression,
adjusting for APEX trial treatment group allocation and
randomisation minimisation variables: baseline WOMAC
Pain score and surgical approach. QALYs were further ad-
justed for baseline utility imbalances [19].
Missing cost and outcome data were imputed using
chained equations for multiple imputation [20], and
Royston’s ‘ice’ command in Stata v13 [21], to generate 20
complete datasets. This method uses regression tech-
niques to estimate missing values, based on the values of
available data. Complete datasets for the primary clinical
outcome were taken from the statistical analysis of the
trial outcomes [5]. The 17 cost categories and four EQ-
5D utility scores (baseline and three follow-up time
points) were imputed jointly, by treatment group alloca-
tion, adjusting for the primary clinical outcome, trial
Table 1 Unit costs for total hip and knee replacement resource use
Resource use Unit cost Assumption Source
Initial inpatient admission
Theatre (per minute) £14.22 Includes implant cost, staff time, overheads,
consumables, facilities
North Bristol NHS Trust Finance
department
Injection of local anaesthesia infiltration (LAI) £2.00 Box of bupivicaine with adrenaline 0.25 %/1 in
200,000 is £20.00; one box contains 10 ampoules
North Bristol NHS Trust Finance
department, management, and
procurement
Recovery (per minute) £3.84 Includes staff time with overheads, consumables,
facilities, and medications administered during
stay; base cost per minute
North Bristol NHS Trust Finance
department
Day in general orthopaedics ward: Frome, Severn,
Kennett, and Cardiac Care Unit
£311 Includes staff time with overheads, consumables,
facilities, and medications administered during
stay; base cost per day
North Bristol NHS Trust Finance
department
Day in other orthopaedics ward: Chew £250 Includes staff time with overheads, consumables,
facilities, and medications administered during
stay; base cost per day
North Bristol NHS Trust Finance
department
Day in high dependency unit £1,356 Includes staff time with overheads, consumables,
facilities, and medications administered during
stay; base cost per day
North Bristol NHS Trust Finance
department
Inpatient admissions following discharge from initial surgery
Revision surgery – Total knee replacement (TKR) £9,439 HB22A major knee procedures for non-trauma,
with major comorbidity and complication (CC)
NHS Reference Costs 2012–2013:
Non-elective long stay
Revision surgery – Total hip replacement (THR) £8,890 HB12A major hip procedures for non-trauma,
with major CC
NHS Reference Costs 2012–2013:
Non-elective long stay
Manipulation under anaesthetic – TKR £2,044 HB24C minor knee procedures for non-trauma,
category 2, without CC
NHS Reference Costs 2012–2013:
Non-elective long stay
Infections £4,124 Infections of bones or joints, with CC Score 5–8 NHS Reference Costs 2012–2013:
Non-elective long stay
Day case procedures – TKR £655 Day case: HB29Z minimal knee procedures for
non-trauma
NHS Reference Costs 2012–2013:
Non-elective day case
Day case procedures – THR £788 Day case: HB19Z minimal hip procedures for
non-trauma
NHS Reference Costs 2012–2013:
Non-elective day case
Nights in hospital for other admissions a £311 Unit cost based on SMH cost per night in
general orthopaedics ward
North Bristol NHS Trust Finance
department
A and E and outpatient visits
Accident and emergency £117 Average of all accident and emergency visits NHS Reference Costs 2012–2013:
Outpatient appointments: 180
Accident & Emergency
Trauma and orthopaedics – consultant led £102 Non-admitted face to face attendance,
follow-up, consultant led
NHS Reference Costs 2012–2013:
Outpatient appointments: 110
Trauma & Orthopaedics
Trauma and orthopaedics – non-consultant led £90 Non-admitted face to face attendance,
follow-up, non-consultant led
NHS Reference Costs 2012–2013:
Outpatient appointments: 110
Trauma & Orthopaedics
Physiotherapy – non-consultant led £39 Non-admitted face to face attendance,
follow-up, non-consultant led
NHS Reference Costs 2012–2013:
Outpatient appointments: 650
Physiotherapy
General Medicine – consultant led £145 Non-admitted face to face attendance,
follow-up, consultant led
NHS Reference Costs 2012–2013:
Outpatient appointments: 300
General Medicine
Neurology – consultant led £157 Non-admitted face to face attendance,
follow-up, consultant led
NHS Reference Costs 2012–2013:
Outpatient appointments: 400
Neurology
Respiratory – consultant led £137 Non-admitted face to face attendance,
first appointment, consultant led
NHS Reference Costs 2012–2013:
Outpatient appointments: 340
Respiratory Medicine
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Table 1 Unit costs for total hip and knee replacement resource use (Continued)
Pain management – consultant led £136 Non-admitted face to face attendance,
follow-up, consultant led
NHS Reference Costs 2012–2013:
Outpatient appointments: 191
Pain management
Vascular – consultant led £133 Non-admitted face to face attendance,
follow-up, consultant led
NHS Reference Costs 2012–2013:
Outpatient appointments: 107
Vascular surgery
Dermatology – consultant led £95 Non-admitted face to face attendance,
follow-up, consultant led
NHS Reference Costs 2012–2013:
Outpatient appointments: 330
Dermatology
Haematology – consultant led £209 Non-admitted face to face attendance,
follow-up, consultant led
NHS Reference Costs 2012–2013:
Outpatient appointments: 303
Clinical Haematology
Community based health services
GP surgery visit £45 Base cost per patient contact with GP
with qualifications, including direct care
staff costs, lasting 11.7 min
Personal Social Services Research
Unit (PSSRU) 2013: 10.8b General
practitioner
GP home visit £114 Base cost per out of surgery visit with GP
with qualifications, including direct care
staff costs, lasting 23.4 min
PSSRU 2013: 10.8b General
practitioner
Phoned GP for advice £27 Base cost per telephone consultation with
GP with qualifications, including direct care
staff costs, lasting 7.1 min
PSSRU 2013: 10.8b General
practitioner
GP Practice nurse visit £13.43 Based on 15.5 min per surgery consultation
using the base cost (£52) of one hour of
face-to-face contact with GP nurse with
qualifications
PSSRU 2013: 10.6 Nurse
(GP practice)
Phoned GP practice nurse for advice £4 Based on 6 min of GP nurse time using the
base cost (£40) of 1 hour of GP nurse time
with qualifications
PSSRU 2013: 10.6 Nurse
(GP practice)
Repeat prescription (without seeing doctor) £11.40 Based on 3 min of GP time, using the base
cost of 1 minute GP patient contact time
(£3.80), with qualifications, including direct
care staff costs
PSSRU 2013: 10.8b General
practitioner
District nurse £18.08 Based on the assumption that the duration
of a district nurse visit is the same as GP
nurse visit (15.5 min) and using the base
cost of 1 hour of community nurse visit
(£70) with qualifications including travel
PSSRU 2013: 10.1 Community nurse
Occupational therapist at home/
GP surgery/clinic
£17 Based on 30 min contact using the base cost
(£34) of 1 hour of occupational therapist
contact with qualifications
PSSRU 2013: 9.2 NHS community
occupational therapist
Community physiotherapist at home/
GP surgery/clinic
£17 Based on 30 min contact using the base cost
(£34) of 1 hour of physiotherapist contact with
qualifications
PSSRU 2013: 9.1 Community
physiotherapist





Home care worker (home help) provided
by social services
£24 Based on 1 hour of face-to-face weekday
contact for independent sector home care
provided for social services
PSSRU 2013: 11.6
Food at home service (meals on wheels) £3.14 Based on one meal a day using the Meals
on Wheels average weekly cost (2012/2013)
of £44, assuming two meals per day, 7 days
a week
PSSRU 2013: 8.1.1 Community
care package for older people:
very low cost
Social worker visits £113 Based on a 30 min visit using the base cost
(£226) of 1 hour of face-to-face contact of
social worker with qualifications
PSSRU 2013: 11.2 Social worker
(adult services)
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Table 1 Unit costs for total hip and knee replacement resource use (Continued)
Social worker telephone calls £39.50 Based on a 30 min telephone call using a
base cost (£79) of 1 hour of client-related
work of a social worker with qualifications
PSSRU 2013: 11.2 Social worker
(adult services)
Home changes and equipment provided by
social services:
All unit costs for home changes and
equipment are based on 3-month loan
period, assuming a 24 months life span
Toilet seat or toilet raiser £1.80 Cost of equipment £14 NRS price – equipment provider
for North Bristol NHS Trust
Dressing aids: socks, shoes, etc. £1.25 Cost of equipment £10 NRS price – equipment provider
for North Bristol NHS Trust
Furniture raisers £2.48 Cost of equipment £20 NRS price – equipment provider
for North Bristol NHS Trust
Perching stool £6.00 Cost of equipment £48 NRS price – equipment provider
for North Bristol NHS Trust
Walker or trolley £7.50 Cost of equipment £60 NRS price – equipment provider
for North Bristol NHS Trust
Crutches £3.75 Cost of equipment £30 NRS price – equipment provider
for North Bristol NHS Trust
Commode £5.69 Cost of equipment £46 NRS price – equipment provider
for North Bristol NHS Trust
Rails and hand grips £2.85 Cost of equipment £23 NRS price – equipment provider
for North Bristol NHS Trust
Bath boards £3.00 Cost of equipment £24 NRS price – equipment provider
for North Bristol NHS Trust
Hospital bed at home £59.88 Cost of equipment £479 Online search for procurement
prices (cheaper range)
Bath lift £44.75 Cost of equipment £358 Online search for procurement
prices (cheaper range)
Chair and stair lift £125.00 Cost of equipment £1000 Online search for procurement
prices (cheaper range)
a When healthcare resource group codes could not be derived because of insufficient information, inpatient admissions were valued multiplying the number of
nights admitted to a ward by the cost of a night in a general orthopaedics ward provided by the North Bristol Trust finance department
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tics: age, sex, body mass index, and dichotomous vari-
ables for education level (high vs medium or low) and
marital status (single vs married or other). QALYs and
grouped cost categories were then recalculated using the
imputed values, and incremental costs and both out-
comes with imputed data were then re-estimated adjust-
ing for the same variables as described in the regression
models above.
The incremental costs and outcomes (QALYs andWOMAC
Pain scores) were presented in a cost-consequences table
and depicted on cost-effectiveness planes. If no treatment
was dominant, an incremental cost-effectiveness ratio
(ICER) was estimated [22]. The ICER is a ratio that divides
the difference in mean costs between arms by the differ-
ence in mean outcomes.
The incremental net monetary benefits (INMB) of the
intervention were estimated in relation to QALYs, given
that this health outcome has recommended UK societal
willingness-to-pay thresholds [10]. The INMB statistic is
estimated by multiplying the incremental health gainobserved in the intervention, compared with control, by
the societal willingness-to-pay thresholds for that health
gain (λ), and then deducting the incremental cost differ-
ence [23]. We used thresholds of £10,000 per QALY, a
threshold closer to recent valuations of QALYs for the
UK [24], and the NICE recommendations of £20,000
and £30,000 per QALY [7]. Positive INMB statistics
indicate a cost-effective intervention, whereby society
is willing to pay more for the health gain than what
the intervention costs. To account for the uncertainty
around the economic results, bootstrapped confidence
intervals (BCI) with 1,000 replications were estimated
for the adjusted costs, outcomes, the INMB statistics,
and ICERs. Bootstrapped costs and effects were depicted
in cost-effectiveness planes [25]. In cost-effectiveness ac-
ceptability curves (CEACs), we illustrated the probability
of the intervention being cost-effective, given a range of
societal willingness-to-pay thresholds. All analyses were
conducted using Stata v13 [26]. In secondary analysis,
we presented the results from a narrower perspective:
the NHS perspective only.
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In one-way deterministic sensitivity analyses, we ex-
plored methodological and sample uncertainty around
the economic results in relation to QALYs and the
WOMAC Pain score. In the first scenario, we assumed
a macro-costing approach to the prescribed medications,
using the national average value of prescriptions costs
per general practitioner (GP) consultation [16], and
multiplying it by the number of the GP consultations
attended by the patient. Secondly, we explored the po-
tential variation in the local trust cost estimates for the
initial inpatient stay: theatre and recovery costs, LAI in-
jection, and daily admission rates to wards, using worst
and best case scenarios where local costs could be up to
50 % higher, or 50 % lower, than our local trust. In the
THR trial, we explored the variation in the results from
excluding two high cost patients: one patient in the con-
trol group, who was an intensive user of home care help,
and one patient in the intervention group, who required
further surgeries with high hospital re-admission costs.Table 2 Mean resource use and cost by APEX trial treatment group
Intervention
N Mean resource use (SD)
Initial inpatient stay
Theatre time (in minutes) 148 99 29
Recovery time (in minutes) 143 103 65
Days in wards 153 5.2 3.3
Secondary care after initial discharge
Inpatient admissions after initial discharge a 115
Orthopaedics appointments 142 1.96 1.2
Physiotherapy appointments 142 0.19 0.8
Accident and emergency visits 142 0.06 0.4
Other appointments 142 0.04 0.3
Community-based resources
GP contacts combined 107 1.90 3.3
Nurse contacts combined 110 1.60 4.1




Prescribed medications a 113
Total NHS cost b 92
Personal social services (PSS)
Home care worker (in hours) 139 1.11 8.1
Meals (food at home services) 137 2.76 24.0
Contacts with social worker 138 0.05 0.5
Home changes a 161
Total NHS+PSS cost b 88
a The category combines different types of resource use, therefore an overall mean
b Total costs computed for patients with complete cost categoriesAll sensitivity analyses were performed from NHS and
PSS perspectives. Imputation models for all cost categor-
ies and utility scores were redone accounting for
changes in sensitivity analysis.
Results and discussion
The APEX trials
The APEX trials recruited 322 patients undergoing THR
and 316 patients undergoing TKR between November 2009
and February 2012. In the THR trial, patients in the inter-
vention group had less pain at 12 months post-operatively,
and were more likely to report none to moderate pain than
severe pain compared to the standard care group. In the
TKR trial, there was no strong evidence that LAI influenced
pain severity at 12 months post-operative. The clinical out-
comes of the APEX trials are reported in full elsewhere [5].
In the THR trial, 88/163 (54 %) patients in the inter-
vention group and 85/159 (53 %) patients in the stand-
ard care group had complete NHS and PSS cost data
(Table 2). In the TKR trial, the corresponding figuresfor total hip replacements (available cases)
Control
Mean cost (SD) N Mean resource use (SD) Mean cost (SD)
£1,407 £411 147 101 31.6 £1,441 £449
£397 £251 144 113 77.4 £435 £297
£1,597 £1,516 154 5.2 2.8 £1,553 £886
£341 £1,847 122 £101 £554
£199 £121 146 1.97 1.4 £201 £138
£7 £32 146 0.23 0.8 £9 £30
£7 £46 146 0.04 0.3 £5 £30
£5 £37 146 0.04 0.3 £7 £59
£61 £113 108 2.66 4.5 £83 £145
£25 £70 114 1.24 2.7 £18 £41
£1 £7 116 0.08 0.5 £1 £8
£4 £19 113 0.58 1.8 £10 £30
£22 £77 120 £21 £55
£3,773 £1,557 87 £3,762 £1,065
£27 £195 144 5.36 56.3 £129 £1,351
£9 £75 138 0.00 0.0 £0 £0
£4 £36 144 0.13 1.1 £7 £59
£1 £3 158 £2 £5
£3,837 £1,642 85 £3,948 £2,108
resource use could not be calculated
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159 (47 %) for the control group (Table 3). Complete
cost and QALY data were available for 159 patients in
the THR trial (49 %) and 142 patients in the TKR trial
(45 %; not reported). Given the amount of missing data,
our primary economic results statistics included imputed
missing cost and outcome data.
Resource use and costs
Tables 2 and 3 show the observed mean and standard de-
viations for the resource use and costs by treatment group,
and by resource use category, for all participants with
data. All available data is reported for each category.
For both the THR and TKR trials, the available case re-
sults indicate that initial inpatient stay cost categories are
similar between groups. Administering intra-operative
LAI does not appear to increase operation time, but may
reduce time in recovery by about 10 min. The length of
stay following recovery was, on average, 5.2 days for bothTable 3 Mean resource use and cost by APEX trial treatment group
Intervention
N Mean resource use (SD)
Initial inpatient stay
Theatre time (in minutes) 142 102 32
Recovery time (in minutes) 140 94 44
Days in wards 147 5.9 3.9
Secondary care after initial discharge
Inpatient admissions after initial discharge a 103
Orthopaedics appointments 128 2.06 1.5
Physiotherapy appointments 128 0.44 2.1
Accident and emergency visits 128 0.16 0.7
Other appointments 128 0.00 0.0
Community Based resources
GP contacts combined 85 2.65 4.3
Nurse contacts combined 90 0.98 1.4




Prescribed medications a 102
Total NHS cost b 70
Personal social services (PSS)
Home care worker (in hours) 135 1.17 12.9
Meals (food at home services) 132 0.14 1.6
Contacts with social worker 133 0.11 1.1
Home changes a 157
Total NHS+PSS cost b 70
a The category combines different types of resource use, therefore an overall mean
b Total costs computed for patients with complete cost categoriesarms of the THR trial, and 5.9 days for the intervention
group of the TKR trial compared to 5.2 days in the stand-
ard care group.
After initial discharge, there were lower readmission
costs for TKR patients in the intervention group,
whereas the reverse was true for patients receiving THR.
Participants in both arms of the two trials had a similar
number of appointments in the period.
In both trials, the intervention group seemed to have
less contacts with a doctor compared with the control
group, but more nurse contacts in the THR trial.
Personal social services costs contributed a minor
amount to the overall costs of delivering treatment
for both types of joint replacement. Total unadjusted
mean NHS and PSS cost was lower in the intervention
group than the control group for both trials. All cost
drivers for these trials display high variability, with
large standard deviations around the categorical mean
cost estimates.for total knee replacements (available cases)
Control
Mean cost (SD) N Mean resource use (SD) Mean cost (SD)
£1,449 £453 145 103 32.9 £1,461 £469
£359 £169 136 104 69.1 £398 £265
£1,789 £1,224 149 5.2 2.9 £1,586 £1,034
£104 £533 110 £296 £907
£209 £149 137 1.99 1.4 £202 £143
£17 £82 137 0.40 1.3 £16 £50
£18 £84 137 0.18 1.2 £20 £145
£0 £0 137 0.03 0.2 £4 £34
£84 £151 102 3.83 5.7 £122 £212
£14 £22 104 1.09 2.7 £16 £43
£5 £19 105 0.25 1.3 £4 £22
£18 £45 107 1.29 3.5 £22 £60
£61 £211 108 £48 £81
£3,807 £1,277 78 £4,255 £1,804
£28 £310 136 1.24 14.4 £30 £346
£0 £5 129 0.11 1.2 £0 £4
£4 £45 134 0.14 1.6 £7 £84
£3 £13 158 £1 £4
£3,811 £1,276 75 £4,303 £2,102
resource use could not be calculated
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Tables 4 (THR) and 5 (TKR) report the costs and out-
come differences between arms. In THR, patients in the
intervention arm had an incremental QALY gain of
0.052 (95 % BCI, 0.01 to 0.09) compared with the con-
trol group. This corresponded to patients in the inter-
vention arm spending on average an estimated 19 more
days in “perfect health” than patients in the control arm.
In TKR, the estimated health benefit gain for the inter-
vention arm was lower and findings were more uncer-
tain, with a mean of 0.009 QALYs gained per patient
in the intervention arm (95 % BCI, −0.04 to 0.057). InTable 4 Total hip replacement: differences in costs and outcomes b
OUTCOMES
QALYs
QALY gain – available cases a
QALY gain – imputed data b
Primary clinical outcome
WOMAC pain score improvement – available cases c
WOMAC pain score improvement – imputed data d
COST
Initial inpatient stay
Total of inpatient stay – available cases a
Total of inpatient stay – imputed data b
Secondary care after initial discharge
Inpatient admissions – available cases a
Inpatient admissions – imputed data b
Outpatient visits – available cases a
Outpatient visits with – imputed data b
Total secondary care cost – available cases a
Total secondary care cost – imputed data b
Community-based resources
Total community-based costs – available cases a
Total community-based costs – imputed data b
Total NHS cost – complete NHS cost cases a
Total NHS cost – imputed data b
Personal social services (PSS)
Total personal social services – available cases a
Total personal social services – imputed data b
Total NHS + PSS cost – complete NHS+PSS cost cases a
Total NHS + PSS cost – imputed data b
a Adjusted for minimisation variables (baseline WOMAC pain score and surgical app
b Adjusted for minimisation variables (and baseline utility for QALYs), robust standa
with 1000 replications
c Adjusted for minimisation variables (baseline WOMAC pain score and surgical app
d Adjusted for minimisation variables, M=20 multiple imputation sets from main starelation to the primary clinical result, patients in the
intervention arm receiving THR experienced a greater
reduction in pain severity at 12 months, by 5.35 points
on the WOMAC Pain scale (95 % CI, 1.33 to 9.34) com-
pared to the control arm. In TKR, there was weaker evi-
dence for the pain reduction observed, with patients in
the intervention arm experiencing less pain at 12
months by 3.33 points on the WOMAC Pain scale (95 %
CI, −1.21 to 7.88).
In both THR and TKR, differences in the imputed and
adjusted NHS, and NHS and PSS costs, indicated that
patients in the intervention group had lower mean costsetween APEX randomised groups
Difference (intervention – control)
N Mean (95 % CI)
216 0.064 (0.018 to 0.110)
322 0.052 (0.011 to 0.094)
281 4.74 (0.95 to 8.54)
322 5.35 (1.33 to 9.34)
273 -£123 (£–364 to £118)
322 -£32 (£–349 to £285)
236 £251 (£–114 to £617)
322 £139 (£–174 to £452)
287 -£2 (£–36 to £32)
322 £4 (£–33 to £42)
231 £251 (£–136 to £639)
322 £143 (£–184 to £471)
202 -£4 (£–51 to £43)
322 -£34 (£–83 to £16)
179 £15 (£–373 to £404)
322 £78 (£–404 to £560)
263 -£83 (£–289 to £123)
322 -£164 (£–418 to £91)
173 -£94 (£–634 to £446)
322 -£86 (£–634 to £462)
roach) and baseline utility for QALYs, robust standard errors
rd errors, M=20 multiple imputation sets, bootstrapped confidence intervals
roach) and baseline utility for QALYs
tistical analysis
Table 5 Total knee replacement: differences in costs and outcomes between APEX randomised groups
Difference (intervention – control)
N Mean (95 % CI)
OUTCOMES
QALYs
QALY gain – available cases a 201 0.010 (−0.039 to 0.060)
QALY gain – imputed data b 316 0.009 (−0.040 to 0.057)
Primary clinical outcome
WOMAC pain score improvement – available cases c 273 3.83 (−0.83 to 8.49)
WOMAC pain score improvement – imputed data d 316 3.33 (−1.21 to 7.88)
COST
Initial inpatient stay
Total of inpatient stay – available cases a 268 £89 (£–194 to £371)
Total of inpatient stay – imputed data b 316 £152 (£–140 to £444)
Secondary care after initial discharge
Inpatient admissions – available cases a 213 -£170 (£–365 to £24)
Inpatient admissions – imputed data b 316 -£239 (£–489 to £11)
Outpatient visits – available cases a 265 £2 (£–47 to £52)
Outpatient visits with – imputed data b 316 £13 (£–43 to £70)
Total secondary care cost – available cases a 203 -£165 (£–391 to £61)
Total secondary care cost – imputed data b 316 -£226 (£–485 to £34)
Community-based resources
Total community based costs – available cases a 170 -£56 (£–142 to £31)
Total community based costs – imputed data b 316 £0 (£–99 to £99)
Total NHS cost – complete NHS cost cases a 148 -£343 (£–822 to £137)
Total NHS cost – imputed data b 316 -£74 (£–490 to £343)
Personal social services (PSS)
Total personal social services – available cases a 259 -£4 (£–95 to £87)
Total personal social services – imputed data b 316 -£4 (£–89 to £82)
Total NHS + PSS cost – complete NHS+PSS cost cases a 145 -£404 (£–924 to £117)
Total NHS + PSS cost – imputed data b 316 -£77 (£–528 to £374)
a Adjusted for minimisation variables (baseline WOMAC c pain score and surgical approach) and baseline utility for QALYs, robust standard errors
b Adjusted for minimisation variables (and baseline utility for QALYs), robust standard errors, M=20 multiple imputation sets, bootstrapped confidence intervals
with 1000 replications
c Adjusted for minimisation variables (baseline WOMAC pain score and surgical approach) and baseline utility for QALYs
d Adjusted for minimisation variables, M=20 multiple imputation sets from main statistical analysis
Marques et al. BMC Medicine  (2015) 13:151 Page 10 of 15than those in the standard care group at 1 year. In THR,
the mean cost per patient in the intervention group was
£32 lower for the initial inpatient stay (95 % BCI, £–349
to £285), £34 lower for community-based health care
costs (95 % BCI, £–83 to £16), and £139 more for re-
admission costs (95 % BCI, £–174 to £452), when com-
pared with the control group, with mean overall NHS
costs higher by £78 (95 % BCI, £–404 to £560). Mean PSS
costs were lower in the intervention arm by £164 per pa-
tient (95 % BCI, £–418 to £91). Therefore, the combined
NHS and PSS mean cost per patient was £86 lower in the
intervention group (95 % BCI, £–634 to £462).In contrast, in TKR, the mean cost per patient for the
initial inpatient stay in the intervention arm was greater
by £152 (95 % BCI, £–140 to £444) and the mean cost
per patient of hospital readmissions was lower by £239
(95 % BCI, £–489 to £11). Therefore, there was an over-
all lower combined NHS and PSS mean cost of £77
(95 % BCI, £–528 to £374) per patient in the interven-
tion group compared with the control group.
Economic results: NHS and PSS perspective
The cost and outcome results indicate that LAI, in
addition to standard analgesia, is the dominant treatment
Marques et al. BMC Medicine  (2015) 13:151 Page 11 of 15option in the two trials: cost-saving and more effective,
both in relation to QALYs and pain severity at 12
months, than current clinical practice. Tables 6 and 7
present the cost-effectiveness results in THR and TKR,
respectively. Given that the intervention was dominant,
no incremental cost-effectiveness ratios were calculated
for the base case results.
In THR, the INMB statistics are positive, even at the
more stringent willingness-to-pay per QALY thresholds.
The mean INMB for the NICE-recommended £20,000
per QALY threshold was of £1,125 (95 % BCI, £183 toTable 6 Total hip replacement economic results
MAIN ANALYSIS: NHS and personal social services (PSS) perspective
Mean QALY gain
Mean NHS+PSS cost difference
Incremental net monetary benefit – lambda £10,000
Incremental net monetary benefit – lambda £20,000
Incremental net monetary benefit – lambda £30,000
SECONDARY ANALYSIS: NHS perspective only
Mean NHS cost difference
Incremental net monetary benefit – lambda £20,000
Incremental Cost per point in WOMAC pain decrease b
SENSITIVITY ANALYSIS: Using macro-costed prescribed medications
Prescribed medications b
Mean QALY gain
Mean NHS+PSS cost difference
Incremental Net Monetary Benefit – lambda £20,000
SENSITIVITY ANALYSIS: 50 % higher local inpatient costs
Initial inpatient stay b
Mean QALY gain
Mean NHS+PSS cost difference
Incremental net monetary benefit – lambda £20,000
SENSITIVITY ANALYSIS: 50 % lower local inpatient costs
Initial inpatient stay b
Mean QALY gain
Mean NHS+PSS cost difference
Incremental net monetary benefit – lambda £20,000
SENSITIVITY ANALYSIS: dropping high cost patients
Mean QALY gain
Mean NHS+PSS cost difference
Incremental net monetary benefit – lambda £20,000
a All results are adjusted for minimisation variables, and baseline utility for QALYs, M
replications, except results noted with b
b Unadjusted estimates with imputed data using M=20 multiple imputation sets
c This confidence interval includes negative ICER values. These negative values indi£2,067). In TKR, our findings also indicate positive
INMB statistics at all willingness-to-pay thresholds, but
more uncertainty around these estimates, with all boot-
strapped confidence intervals crossing the null.
Figure 1 plots the 1,000 replications of the adjusted
bootstrapped incremental cost-effectiveness estimates in
the cost-effectiveness planes and the corresponding
CEACs for the various willingness-to-pay per QALY
thresholds. Most estimates fall within the southeast
quadrant of the plane, indicating the dominance of the
intervention over standard care, more notably so forDifference (intervention – control) a
N Mean (95 % CI) P value
322 0.052 (0.017 to 0.087) 0.004
322 –£86 (£–571 to £399) 0.730
322 £606 (£–55 to £1,266) 0.072
322 £1,125 (£183 to £2,067) 0.019
322 £1,645 (£385 to £2,905) 0.011
322 £78 (£–347 to £502) 0.720
322 £961 (£50 to £1,873) 0.039
322 £16 (£–16,591 to £16,622)c 0.999
322 –£24 (£–28 to £–20)
322 0.052 (0.017 to 0.087) 0.004
322 –£107 (£–590 to £376) 0.660
322 £1,666 (£406 to £2,925) 0.010
322 –£50 (£–156 to £56)
322 0.052 (0.017 to 0.088) 0.004
322 –£106 (£–697 to £485) 0.730
322 £1,151 (£121 to £2,181) 0.028
322 –£8 (£–44 to £27)
322 0.050 (0.015 to 0.086) 0.006
322 –£44 (£–445 to £358) 0.830
322 £1,051 (£164 to £1,938) 0.020
320 0.052 (0.016 to 0.088) 0.004
320 –£73 (£–449 to £302) 0.70
320 £1,121 (£ 215 to £2,026) 0.015
=20 multiple imputation sets, bootstrapped confidence intervals with 1000
cate that the intervention is dominant
Table 7 Total knee replacement economic results
Difference (intervention – control) a
N Mean (95 % CI) P value
MAIN ANALYSIS: NHS and personal social services (PSS) perspective
Mean QALY gain 316 0.009 (−0.030 to 0.049) 0.64
Mean NHS+PSS Cost difference 316 –£77 (£–451 to £296) 0.68
Incremental net monetary benefit – lambda £10,000 316 £171 (£–452 to £793) 0.59
Incremental net monetary benefit – lambda £20,000 316 £264 (£–710 to £1,238) 0.60
Incremental net monetary benefit – lambda £30,000 316 £357 (£–992 to £1,707) 0.60
SECONDARY ANALYSIS: NHS perspective only
Mean QALY gain 316 0.009 (−0.030 to 0.049) 0.64
Mean NHS cost difference 316 –£74 (£–414 to £266) 0.67
Incremental net monetary benefit – lambda £20,000 316 260 (£–690 to £1,210) 0.59
SENSITIVITY ANALYSIS: using macro-costed prescribed medications
Prescribed medications b 316 –£14 (£–21 to £ –6)
Mean QALY gain 316 0.009 (−0.030 to 0.049) 0.64
Mean NHS+PSS cost difference 316 –£121 (£–491 to £249) 0.52
Incremental net monetary benefit – lambda £20,000 316 £308 (£–665 to £1,281) 0.53
SENSITIVITY ANALYSIS: 50 % higher local inpatient costs
Initial inpatient stay b 316 –£258 (£164 to £353)
Mean QALY gain 316 0.008 (−0.032 to 0.047) 0.70
Mean NHS+PSS cost difference 316 –£2 (£–483 to £478) 0.99
Incremental net monetary benefit – lambda £20,000 316 £159 (£–882 to £1,200) 0.76
SENSITIVITY ANALYSIS: 50 % lower local inpatient costs
Initial inpatient stay b 316 £84 (£–66 to £234)
Mean QALY gain 316 0.006 (−0.034 to 0.045) 0.79
Mean NHS+PSS cost difference 316 –£143 (£–423 to £137) 0.32
Incremental net monetary benefit – lambda £20,000 316 £253 (£–674 to £1,180) 0.59
a All results are adjusted for minimisation variables, and baseline utility for QALYs, M=20 multiple imputation sets, bootstrapped confidence intervals with 1000
replications, except results noted with b
b Unadjusted estimates with imputed data using M=20 multiple imputation sets
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around the economic results, with a probability of LAI
being cost-effective in TKR only slightly over 60 % at the
£20,000 threshold. In THR, there is over 98 % probabil-
ity of LAI being cost-effective at £20,000 per QALY and
over 95 % at £10,000 per QALY.
Economic results: NHS perspective
From an NHS perspective, LAI in addition to usual anal-
gesia is no longer a dominant strategy in THR, albeit
highly cost-effective, with an INMB of £961 (95 % BCI,
£50 to £1,873; Table 6). There is considerably more un-
certainty around the cost-effectiveness estimate in rela-
tion to decrease in pain severity measured by the
WOMAC Pain scale at £16 per decrease in one point of
pain (95 % CI, £–16,591 to £16,622). In TKR, LAI isstill the cheapest and most effective intervention, in rela-
tion to both QALYs, with an INMB statistic of £260
(λ = 20,000; 95 % BCI, –£690 to £1,210, Table 7), and
WOMAC pain, from an NHS perspective only.
Sensitivity analysis results
Our results in THR (Table 6) are robust to costing
method of medication use, with an INMB statistic at the
£20,000 per QALY threshold only slightly higher than
base case. Varying local trust cost estimates during the
initial patient stay by a factor of 50 % higher or lower
did not alter our results, whereby the intervention is still
dominant in both surgeries. In THR, the INMB statistics
range from £1,051, using lower local costs, to £1,151,
when higher local costs were used, compared with
£1,125 in the base case. In TKR (Table 7), the respective
a) b)
Fig. 1 a. Total hip replacement: primary and secondary analyses cost-effectiveness plane and cost-acceptability curve. b. Total knee replacement:
base care cost-effectiveness plane and cost-acceptability curve
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base case. Due to changes in the components of the im-
putation model, QALY estimates vary slightly, particu-
larly in TKR for these scenarios. In the scenario where
we drop two high cost patients in THR, LAI is also the
dominant treatment option with an INMB statistic of
£1,121 (λ = 20,000; 95 % CI, £215 to £2,026). Figure 2a
portrays the cost-effectiveness planes and CEACs for the
scenarios, displaying probabilities of LAI being the cost-
effective treatment option of over 98 % at the £20,000
per QALY threshold in THR. For TKR (Fig. 2b), sensitiv-
ity analysis results are consistent with base case results
with just over 60 % probability of LAI being cost-
effective at the £20,000 threshold.
Discussion
Our findings suggest that administering LAI before wound
closure is a cost-effective treatment option compared to
current clinical analgesia regimens in both primary THR
and TKR surgeries. The evidence is stronger for THR than
TKR, with large positive INMB and a probability of LAI
being cost-effective of over 95 % across all scenarios.
There is no strong evidence for the positive INMB statis-
tics for TKR, although results point to LAI being the dom-
inant treatment option with a 62 % probability of beingcost-effective at current NICE thresholds of £20,000 per
QALY. There was little difference in costs between the
two arms in both trials, with the cost-effectiveness results
being driven by the QALY gain, which is larger in the THR
trial. This higher QALY gain in the THR also accounts for
the difference in economic results between trials. From an
NHS perspective, in relation to THR, the intervention is
no longer dominant, but still highly cost effective.
Our study is the first, to our knowledge, to report a trial
based economic evaluation of LAI in the longer-term for
patients receiving THR and TKR. The economic results of
our trials reinforce the effectiveness results, and together
provide evidence that the intervention is both effective
and cost-effective in THR. There is more uncertainty
around the effectiveness and cost-effectiveness results for
TKR, where patients already benefit from a femoral nerve
block in standard care. Given that there are no safety con-
cerns with the treatment [27, 28], it should be recom-
mended for use in patients having a THR.
Our study is not without limitations. The economic
evaluation was carried out alongside the APEX trials,
which were powered to detect a difference in the pri-
mary clinical outcome between treatment groups, but
not in the cost-effectiveness outcomes. Collection of re-
source use data, particularly community-based health
a) b)
Fig. 2 a. Total hip replacement: Sensitivity analyses cost-effectiveness planes and cost-acceptability curves. b. Total knee replacement: Sensitivity
analyses cost-effectiveness planes and cost-acceptability curves
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completed by postal questionnaires at three follow-up
points. This led to a substantial amount of missing data
and imputation was therefore needed. The imputed
value estimates varied substantially from available case
estimates. Patients with complete cost and QALY data
had better pain outcomes. This was, however, accounted
for in our imputation model, which included WOMAC
Pain outcomes as a predictor of costs and QALYs, for
a more conservative economic result. It would, there-
fore, be unlikely that the interventions would not to be
cost-effective at current NICE recommended thresh-
olds, even if complete cost and QALY data had been
obtained. Local estimates for the initial hospital were
used rather than national tariffs to allow for the disag-
gregation of this stay. This could potentially limit thegeneralisability of the results to other hospital locations.
However, there were only minor differences in resource
use in the micro-costed items. A sensitivity analysis
which altered these local unit costs showed the initial
results to be robust.
Conclusions
Our findings suggest that administering LAI before
wound closure is a cost-effective treatment option com-
pared to current clinical analgesia regimens in both pri-
mary THR and TKR surgeries. The evidence, because of
larger QALY gains, is stronger for THR. In TKR, there
is more uncertainty around the economic result, and
smaller QALY gains. Results, however, point to LAI be-
ing cheaper than standard analgesia, which already in-
cludes a femoral nerve block.
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